Adenosine and Metabotropic Glutamate Receptors Are Present in Blood Serum and Exosomes from SAMP8 Mice: Modulation by Aging and Resveratrol

Alejandro Sánchez-Melgar 1, José Luis Albasanz 1,* , Christian Griñán-Ferré 2✉, Mercè Pallás 2✉ and Mairena Martín 1

1 Department of Inorganic, Organic and Biochemistry, Faculty of Chemical and Technological Sciences, School of Medicine of Ciudad Real, Regional Center of Biomedical Research (CRIB), University of Castilla-La Mancha (UCLM), 13071 Ciudad Real, Spain; alejandro.sanchez@uclm.es (A.S.-M.); mairena.martin@uclm.es (M.M.)

2 Department of Pharmacology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Neuroscience, University of Barcelona, 08028 Barcelona, Spain; christian.grinan@ub.edu (C.G.-F.); pallas@ub.edu (M.P.)*

Correspondence: jose.albasanz@uclm.es; Tel.: +34-926295300 (ext. 6279)

Received: 3 June 2020; Accepted: 2 July 2020; Published: 7 July 2020

Abstract: Adenosine (ARs) and metabotropic glutamate receptors (mGluRs) are G-protein coupled receptors (GPCRs) that are modulated in the brain of SAMP8 mice, an animal model of Alzheimer’s disease (AD). In the present work, it is shown the presence of ARs and mGluRs in blood serum and derived exosomes from SAMP8 mice as well as its possible modulation by aging and resveratrol (RSV) consumption. In blood serum, adenosine A1 and A2A receptors remained unaltered from 5 to 7 months of age. However, an age-related decrease in adenosine level was observed, while 5′-Nucleotidase activity was not modulated. Regarding the glutamatergic system, it was observed a decrease in mGluR5 density and glutamate levels in older mice. In addition, dietary RSV supplementation caused an age-dependent modulation in both adenosinergic and glutamatergic systems. These GPCRs were also found in blood serum-derived exosomes, which might suggest that these receptors could be released into circulation via exosomes. Interestingly, changes elicited by age and RSV supplementation on mGluR5 density, and adenosine and glutamate levels were similar to that detected in whole-brain. Therefore, we might suggest that the quantification of these receptors, and their corresponding endogenous ligands, in blood serum could have predictive value for early diagnosis in combination with other distinctive hallmarks of AD.

Keywords: G-protein coupled receptors; adenosine receptors; metabotropic glutamate receptors; exosomes; blood serum; resveratrol; Alzheimer’s disease; SAMP8 mice

1. Introduction

Alzheimer’s disease (AD) is the most common neurodegenerative disease, with around 50 million people affected. It is expected that by 2050 the incidence of AD will triplicate worldwide [1]. Unfortunately, when AD is diagnosed it is too late to reverse the neuronal death and cognitive decline. Therefore, it is necessary to find new biomarkers for early diagnosis to get preventive treatment. In the last years, imaging techniques such as positron emission tomography (PET) have provided useful information to aid in diagnosis [2], but this information alone appears to be inconclusive. Extensive studies on biomarkers of AD in cerebrospinal fluid (CSF) have evidenced the presence of amyloid-β (Aβ) peptide [3,4], Tau as well as phosphorylated Tau (p-Tau) [5,6], and even a potential association with apolipoprotein E (APOE) ε4 allele [3,7]. However, CSF analysis of AD biomarkers is not
very useful as a routine tool for early diagnosis of AD as it requires a highly invasive lumbar puncture, and the results obtained seem to be also inconclusive [8]. In the last decade, the blood-based biomarkers are getting the attention of researchers due to it is a far-less invasive method [9]. Likewise, it has been reported the presence in blood of some potential biomarkers ranging from oxidative stress processes, mitochondrial dysfunction, neuronal injury, and pro-inflammatory cytokines, even Aβ, all of them distinctive hallmarks in AD [10,11]. However, the quantification of Aβ peptide density in peripheral blood seems to be highly variable and not useful for blood-based AD diagnosis [12].

Adenosine is a nucleoside widespread in the body that mainly operates through four adenosine receptors (ARs) and whose levels can be fine-tune regulated by its converting enzyme 5′-Nucleotidase [13]. ARs belong to G-protein coupled receptors (GPCRs) family and have been classified into A₁, A₂A, A₂B, and A₃ [14,15]. In the brain, adenosine is widely known as a modulator of neurotransmission, displaying a crucial role under physiological and pathological conditions [16,17]. Both A₁ and A₂A receptors are the most abundant ARs in the central nervous system (CNS), and its role in neurodegenerative diseases, including AD, has been intensely investigated [17]. It has been reported that A₁ and A₂A were altered in the frontal cortex [18], as well as adenosine level and 5′-nucleotidase activity in several cortical areas from post-mortem human brain of AD patients [19].

Glutamate is the main excitatory neurotransmitter in the CNS, whose action is mediated through ionotopic and metabotropic receptors [20]. The physiological role of this neurotransmitter is essential in synaptic transmission, neuronal plasticity, learning, and memory. Nevertheless, excessive concentration of glutamate may trigger ionotopic receptors activation that leads to excitotoxicity, neuronal dysfunction, and subsequent neuronal death. Indeed, glutamate-mediated excitotoxicity has been related to several neurological and neurodegenerative diseases including AD [21]. Interestingly, metabotropic glutamate 5 receptor (mGluR₅), which belongs to the GPCR family, has been postulated as a potential therapeutic target since it was reported that amyloid-β (Aβ) directly interacts with mGluR₅ [22]. In line with this, the group I mGluRs (mGluR₁ and mGluR₅) was found to be altered in the frontal cortex from the post-mortem human brain of AD patients [23].

Resveratrol (RSV) has been considered as an anti-aging molecule with several beneficial properties for health ranging from cardio- [24], and neuroprotection [25] as well as an antitumoral [26,27] and immunoregulatory [28] action, among others. Recently, it has been described the modulatory effect of RSV on adenosinergic [29] and glutamatergic systems [30] in the brain of SAMP8 mice from 5 and 7 months of age.

It is well established that receptors such as GPCRs or ionotropic receptors are mainly located into the plasma membrane, except for some receptors that are present in intracellular compartments (e.g., estrogen receptors in the nucleus). However, it has been recently reported the presence of receptors in circulation. The biological significance of those results remains to be clarified but the authors reported a potential correlation with some particular diseases [31,32], suggesting a predictive value in diagnosis.

Now, we show for the first time the presence of ARs and mGluRs, as well as their corresponding endogenous ligands, in blood serum and derived exosomes in SAMP8 mice. Moreover, some components from both adenosinergic and glutamatergic systems seem to be strongly affected by RSV supplementation. Intriguingly, changes in adenosine and glutamate levels, and mGluR₅ density associated with aging detected here mimics those previously reported by our group in the brain from SAMP8 mice.

2. Materials and Methods

2.1. Animals and Resveratrol Diet

A total of 26 male SAMP8 mice from 5 and 7 months-old (mo) were used for this study. Mice received a standard diet (2018 Teklad Global 18% Protein Rodent Maintenance Diet, ENVIGO, Barcelona, Spain) or the same diet supplemented with trans-resveratrol (RSV) (1 g/kg, Mega Resveratrol,
Candlewood Stars, Inc., Danbury, CT, USA), starting from the weaning or 4 mo for 5 and 7 mo mice, respectively (Scheme 1). All the mice had food and water ad libitum and were kept in standard conditions of temperature (22 ± 2 °C) and 12:12-h light-dark cycles (300 lux/0 lux). There were no diet intake related differences (i.e., diet taste preference). There were not significant changes in food intake between groups. Food intake was routinely controlled, and revealed that, by mean, each animal eats 5 g of chow by day. Therefore, this RSV supplementation results in a daily dose of 160 mg/kg (body weight). All experimental procedures involving animals were performed followed by standard ethical guidelines European Communities Council Directive 86/609/EEC and by the Institutional Animal Care and Use Committee of the University of Barcelona (670/14/8102, approved at 11/14/2014) and by Generalitat de Catalunya (10291, approved 1/28/2018). All efforts were made to minimize the number of mice used and their suffering.

**Scheme 1.** Resveratrol (RSV) treatment schedule followed in the present work.

### 2.2. Blood Serum Collection

Whole blood serum samples from SAMP8 mice were collected by using 4.4 mL, 75 × 13 mm, Z-Gel tubes, blood allowed to clot by leaving it undisturbed at room temperature, and finally clot was removed by centrifugation at 2000×g for 10 min in a refrigerated centrifuge. The supernatant was collected and stored at −80 °C.

### 2.3. Blood Serum-Derived Exosomes Isolation

Serum-derived exosomes were isolated by using ExoQuick (Ref: EXOQ5A-1, System Biosciences, Palo Alto, CA, USA). The procedure was carried out by following the manufacturer’s indications. Serum was centrifuged at 3000×g for 15 min to remove cells and debris and the supernatant was collected. ExoQuick solution was then mixed with the supernatant and incubated at 4 °C for 30 min. ExoQuick/Serum mixture was centrifuged at 1500×g for 30 min. Pellet was resuspended in saline solution and stored at −80 °C for further experimentation.

### 2.4. Western Blotting Analysis

For western blotting assays, blood serum samples or isolated exosomes (30 μg of protein) were mixed with loading buffer containing 0.125 M Tris (pH 6.8), 20% glycerol, 10% β-mercaptoethanol, 4% SDS and 0.002% bromophenol blue, and heated at 65 °C for 5 min. Protein was electrophoresed on a 10% SDS-PAGE gel using a mini-protean system (Bio-Rad, Madrid, Spain) with molecular weight standards (Bio-Rad). Protein transfer to nitrocellulose membranes was carried out in iBlot Dry Blotting System (Invitrogen, Madrid, Spain). Membranes were washed with PBS-Tween 20, blocked with PBS containing 5% skimmed milk, and then incubated with the primary antibodies at 4 °C overnight at 1:1000 dilution for anti-A2A R (Abcam, ab79714), anti-A1R (Abcam, ab124780, Cambridge, UK), anti-mGluR5 (GeneTex, GTX133288, Taiwan, R.O.C.), and anti-C9D9 (Santa Cruz Biotechnology, sc-13118, Dallas, TX, USA). Albumin stained with Ponceau Red was used as a loading control. After rinsing, the membranes were incubated with the corresponding secondary antibody (Bio-Rad, GAMPO 170-6516, GARPO 172-1019, Madrid, Spain) at a dilution of 1:5000 in PBS containing
5% skimmed milk for 1 h. Antigen was visualized using the ECL chemiluminescence detection kit (Amersham, Madrid, Spain) in a G: Box chamber, and specific bands were quantified by densitometry using GeneTools software (Syngene, Cambridge, UK).

2.5. 5′-Nucleotidase Activity Assay

5′-Nucleotidase activity was measured as previously reported [33]. Briefly, 30 µg of protein from blood serum were pre-incubated at 37 °C for 10 min in the reaction medium (50 mM Tris-HCl, 5 mM MgCl₂ pH 9). Then, the reaction was initiated by adding AMP at the final concentration 500 µM and stopped 20 min later by adding 10% trichloroacetic acid. The samples were chilled on ice for 10 min and then centrifuged at 12,000×g for 4 min at 4 °C. The supernatants were used to measure inorganic phosphate released using KH₂PO₄ as Pi standard. The nonenzymatic hydrolysis of AMP was corrected by adding samples after trichloroacetic acid. Incubation times and protein concentration were selected in order to ensure the linearity of the reactions. All samples were run in duplicate. Enzymatic activity is expressed as nmol Pi released/min · mg protein.

2.6. Adenosine Level Quantification by HPLC

Chromatographic analysis was performed with Ultimate 3000 U-HPLC and data peaks were processed with Chromaleon 7 (ThermoFisher, Madrid, Spain) as previously described [17]. HPLC diode array was used working at 254 nm wavelength. Purine standards and samples (40 µL) were injected in C18 column of 4.6 mm × 250 mm, 5 µm particle size. Two solvents were used for gradient elution: solvent A 20 mM phosphate buffer solution (pH 5.7), and solvent B 100% methanol. The gradient was 95% (11 min), 80% (9 min), and 95% (2 min) in solvent A. The total run time was 22 min with a constant flow rate of 0.8 mL/min at 25 °C. The retention time for adenosine was 15.5 min. Adenosine level was obtained by interpolation from the standard curve. The standard curves were obtained by using five concentrations of adenosine ranging from 0.1–500 µM. Data were then normalized to the protein concentration of each analyzed blood serum sample.

2.7. Glutamate Level Quantification

The total glutamate level was quantified as indicated in the manufacturer’s protocol (Molecular Probes Ref. A12221). Briefly, 50 µL of the diluted samples were mixed into 96-black well plate with 50 µL of reaction mix containing Amplex Red, horseradish peroxidase, L-alanine and L-glutamate-pyruvate transaminase and L-glutamate oxidase. Fluorescence was measured in kinetic mode for 30 min. Data were then interpolated to a standard curve and normalized to the amount of protein. Excitation/emission was detected at Ex/Em = 530/590 nm.

2.8. Protein Quantification

Total protein was quantified by using the Lowry method.

2.9. Statistical and Data Analysis

Data are means ± SEM. Statistical analysis was according to Student’s t-test. Differences between mean values were considered statistically significant at p < 0.05. GraphPad Prism 6.0 program was used for statistical and data analysis (GraphPad Software, San Diego, CA, USA).

3. Results

3.1. Adenosine A₁ and A₂A Receptors Modulation in Blood Serum

Adenosine A₁ and A₂A receptors were detected in serum from SAMP8 mice. As shown in Figure 1, there is not a significant difference in the A₁ receptor level between 5 and 7 mo mice (Figure 1a). However, RSV treatment caused a significant decrease in the density of this receptor in 5 mo mice (Figure 1b), whereas no changes were detected in RSV-treated 7 mo mice when compared with their
corresponding untreated mice (Figure 1c). Concerning A2A receptors, no changes on the level of these receptors were observed either associated with age (Figure 2a) or in 5 mo RSV-treated mice (Figure 2b), but a higher level of A2A receptors was detected in RSV-treated 7 mo mice when compared with their corresponding control (Figure 2c).

**Figure 1.** Adenosine A1 receptors presence and modulation in serum from SAMP8 mice. Isolated serum from SAMP8 mice was used to detect and quantify the adenosine A1 receptor (A1R) by Western blotting. (a) Level of A1R in control mice of different ages (5 and 7 months). (b) Effect on A1R levels after RSV treatment in 5 months-old mice. (c) Effect on A1R levels after RSV treatment in 7 months-old mice. Data are the mean ± SEM of five to six different samples. Albumin was used as a loading control and visualized by Ponceau red staining. *p < 0.05 significantly different from the corresponding control, according to the Student’s t-test.

**Figure 2.** Adenosine A2A receptors presence and modulation in serum from SAMP8 mice. Isolated serum from SAMP8 mice was used to detect and quantify the adenosine A2A receptor (A2AR) by Western blotting. (a) Level of A2AR in control mice of different ages (5 and 7 months). (b) Effect on A2AR levels after RSV treatment in 5 month-old mice. (c) Effect on A2AR levels after RSV treatment in 7 month-old mice. Data are mean ± SEM of five different samples. Albumin was used as a loading control and visualized by Ponceau red staining. *p < 0.05 significantly different from the corresponding control, according to the Student’s t-test.

3.2. Adenosine Level and Its Converting Enzyme in Blood Serum

We next analyzed adenosine level and the activity of its converting enzyme, 5′-nucleotidase. Adenosine levels were found to be strongly decreased by age, as shown in Figure 3a. However, an age-dependent change on this nucleoside level was observed after RSV treatment. Accordingly, a significant decrease and increase in adenosine levels were detected in 5 and 7 mo RSV-treated mice, respectively, when compared to their age-matched controls. 5′-Nucleotidase activity
Figure 3. Adenosine levels and 5′-nucleotidase activity in serum from SAMP8 mice. Isolated serum from SAMP8 mice was used to measure adenosine level and its converting enzyme. (a) Adenosine levels and (b) 5′-Nucleotidase activity were quantified as described in Methods. Data are mean ± SEM of five-eight different samples. ** p < 0.01 and *** p < 0.001 significantly different from their corresponding controls, and +++ p < 0.001 significantly different from 5 months old untreated mice, according to Student’s t-test.

3.3. mGlu5 Receptors and Glutamate Level Modulation in Blood Serum

Similarly to ARs, some components of the metabotropic glutamatergic system were detected in blood serum. Regarding mGluR5, a significant reduction associated with aging was observed (Figure 4a). Nevertheless, RSV treatment did not cause any effect on mGluR5 receptor density either 5 mo (Figure 4b) or 7 mo mice (Figure 4c). On the other hand, the glutamate level was strongly decreased by age. Yet, RSV treatment induced an age-dependent effect. A lower glutamate level was detected in 5 mo RSV-treated mice, while higher levels were found in 7 mo RSV-treated mice when compared to their corresponding controls (Figure 5). Albumin level, which has been used as a gel loading control, was quantified in the different conditions studied. The level of this protein was unchanged by age or RSV-treatment (Figure S1).

Figure 4. Metabotropic glutamate 5 receptors presence and modulation by RSV in serum from SAMP8 mice. Isolated serum from SAMP8 mice was used to detect and quantify the metabotropic glutamate 5 receptors (mGluR5) by Western blotting. (a) Level of mGluR5 in control mice of different ages (5 and 7 months). (b) Effect on mGluR5 levels after RSV treatment in 5 month-old mice. (c) Effect on mGluR5 levels after RSV treatment in 7 month-old mice. Data are mean ± SEM of four to six different samples. Albumin was used as a loading control and visualized by Ponceau red staining. * p < 0.05 significantly different from the corresponding control, according to the Student’s t-test.
Figure 6. Glutamate level in serum from SAMP8 mice. Blood serum from SAMP8 mice was used to measure the glutamate level normalized to the amount of protein, as described in Methods. Data are mean ± SEM of five-eight different samples. * p < 0.05, ** p < 0.01 and +++ p < 0.001 were significantly different from their corresponding control or indicated values, according to the Student’s t-test.

3.4. Adenosine A₁ and A₂A and mGlu5 Receptors Presence in Blood Serum-Derived Exosomes

To further investigate whether these receptors can be found into circulation in exosomes, we isolated blood serum-derived exosomes by using ExoQuick, as described in Methods. A strong immunoreactivity against CD9, considered an exosome marker, was detected in the exosome fraction (Figure 6a). In addition, A₁R, A₂AR, and mGluR5 were also detected, and quantified in exosomes (Figure 6b).

Figure 6. Adenosine A₁, A₂A and metabotropic glutamate 5 receptors in serum-derived exosomes from SAMP8 mice. Serum-derived exosomes from SAMP8 mice were isolated following the manufacturer’s indications, and different proteins were detected by Western-blotting as described in “Methods”. (a) Representative gel bands of mGluR5, A₂AR, A₁R, and CD9 presence in exosomes. (b) Level of mGluR5, A₂AR, A₁R, in control (C) and resveratrol supplemented (RSV) mice of different ages (5 and 7 months). Data are mean ± SEM of five to eight different samples. CD9 was used as a loading control. * p < 0.05, and ** p < 0.01 significantly different from the corresponding control, according to the Student’s t-test.
4. Discussion

Results presented herein show, for the first time, the presence of ARs and mGluRs in blood serum and exosomes, as well as their modulation by aging and RSV supplementation. Furthermore, adenosine and glutamate levels were also modulated by age and RSV supplementation.

SAMP8 mice have been considered an aging and an AD model. Accordingly, it has been reported similarities to the pathophysiology of aging in the human brain and the early cognitive decline [34] together with other distinctive hallmarks of AD such as Aβ overexpression, upregulation of Presenilin-2 and high levels of p-Tau in the hippocampus, but lower expression of Apolipoprotein-E as compared to their respective control mice [35]. The lifespan for SAMP8 is around 10 months of age [36]. According to the half lifespan of a common mice strain and the maturational rates mouse vs. human, 2 mo represents a young human, and 4 mo a middle-aged individual, when our RSV treatment starts. We evaluated SAMP8 mice at 5 (middle aged, 38–47 years) and 7 months (old individual, 56–69 years) [37].

The modulation of ARs and mGluRs has been reported in different brain areas of AD patients [18,23]. In the whole-brain from SAMP8 mice, we have reported an age-related downregulation and desensitization of the A1 receptor whereas A2A was found to be fully functional [29,38]. Also mGluR5 significantly decreased with aging [30]. These previous data suggest SAMP8 mice as a suitable model for ARs and mGluRs related research on neurodegenerative diseases.

Now, our results indicate that A1, A2A, and mGlu5 receptors are present in blood serum from SAMP8 mice. These receptors could be released into circulation likely via exosomes since they were detected in blood serum-derived exosome as well as CD9, a tetraspanin widely used as exosome marker [39–41]. The presence of different GPCRs in blood serum has been evidenced before. Corticotropin releasing-factor receptors I/II (CRF receptor I/II) were reported as circulating receptors in extracellular vesicles (EVs) from blood serum [32]. Additionally, the purinergic receptor P2×7 was found as EVs cargo in human blood serum. Although P2×7 receptors were identified as a full-length molecule, some bands with lower molecular weight were also detected. In fact, the authors suggested that proteolytic cleavage could not be excluded from shedding into the circulation of this receptor [31]. We detected circulating A1R at 35 kDa when in brain tissue it was detected at 37 kDa. This discrete but lower molecular weight of circulating receptors found in serum when compared to the brain receptors could be related to a proteolytic cleavage during the releasing process. However, brain A2AR can be detected at 45 kDa, but circulating A2AR was detected at 50 kDa. The higher molecular weight observed in this receptor could be due to glycosylation or related-mechanism likely to facilitate their transport in blood serum. In accordance, circulating CRF receptor I/II were also detected at a discrete but higher molecular weight in human blood serum [32]. Regarding mGluR5, it was found a band at 125–130 kDa, which is in line with the predicted weight estimated by the manufacturer’s indications, suggesting that this receptor might be released as a full-length molecule.

Some authors found β-actin in plasma and not significant changes in its density were observed in major depressive disorder (MDD), thus allowing their use as a loading control for plasma-based Western blotting [42]. However, we found some density changes associated with age in SAMP8 serum, as previously reported in human skeletal muscle cells [43]. Therefore, we instead used albumin, the most abundant protein in serum, as a loading control. It has been postulated a connection between dementia and blood-brain barrier (BBB) dysfunction [44], which could lead to altered CSF/serum albumin index due to the BBB disruption [45]. Here, we did not found changes in albumin density either associated with age or RSV supplementation (Supplemental Figure S1).

It is widely known that both adenosine A1 and A2A receptors [46] and their endogenous ligand [47] are unevenly distributed throughout the healthy human brain. Adenosine A1 receptor is the most abundant subtype within the CNS except for the striatum, putamen, and basal ganglia, where the A2A receptor is highly abundant [48]. This uneven expression of ARs within the CNS is accompanied by differential ARs modulation in each brain area of AD patients. A widespread lower level of A1 receptors in AD patients as compared to healthy individuals was observed by PET [49]. Similarly, an age-related loss of this receptor in the whole-brain of SAMP8 mice was also described [29,38]. In contrast,
an increased density of A1 receptors was detected in the frontal cortex from the post-mortem human brain of AD patients [18]. On the other hand, it was not found a clear alteration on the A2A receptors density detected by PET during aging in the human brain [50]. These results are in line with a previous work where no changes were found on the A2A receptors density in plasma membrane from the whole-brain in SAMP8 mice during aging [29]. However, it has been reported a significantly increased density of A2A receptors in the limbic cortex but not in the striatum in aged rats [51], as well as an up-regulation of A2A receptors in the frontal cortex from post-mortem brain of AD patients [18].

Regarding adenosine levels, it has been described a different pattern of distribution and modulation of this nucleoside together with the activity of its converting enzymes in several areas from the human brain cortex of AD, even at the early stages of the disease, as compared to healthy controls [19]. Due to area, age, and gender dependence of the nucleoside system in the brain [52,53], it is difficult to conclude how adenosine level is modulated in the whole-brain from AD patients. The lack of data about a global change in adenosine level in the whole brain in AD avoids its possible correlation with the increased adenosine levels reported in serum [54]. However, we found an age-related decrease of adenosine in SAMP8 serum, associated with a reduced level in the whole-brain of these mice [29]. In humans, the quantification of plasma adenosine concentration in 1141 patients revealed that advancing age may be associated with lower adenosine levels [55]. The reported gradual increase in the activity of serum adenosine deaminase could be a contributing factor [56].

An interesting but less investigated enzyme in AD is the 5′-Nucleotidase activity. A previous study demonstrated a significant decrease in this enzymatic activity in the frontal cortex of AD patients as compared to age-matched healthy controls [19]. This activity was also decreased in the whole-brain of aged SAMP8 mice [29]. However, the absence of changes related to age on the 5′-Nucleotidase activity in blood serum, besides a dramatically lower activity in serum than in the brain [29], makes it difficult to establish an association between serum and brain enzymatic activities.

The pathological role of mGluR5 in the CNS has been the focus of intense research since a direct interaction of Aβ and mGluR5 was reported [22,57]. mGluR5 plays a crucial role in the cognitive decline, and it could be involved in the pathogenesis and progression of AD [58,59]. However, little is known about the modulation of this receptor in the brain from AD patients. Previous work reported an absence of changes in the mGlu5 density in the frontal cortex from post-mortem samples of AD patients, despite an impaired functionality of group I mGluRs observed even at early stages [23]. However, an in vivo study by PET revealed a downregulation of mGluR5 caused by Aβ in the limbic system in the 5xFAD mouse model as compared to wild type [60]. We have recently described a significant age-associated decrease in mGluR5 density in the whole-brain of SAMP8 mice [30]. Interestingly, in the present work, a significant and robust reduction in mGluR5 density was also detected in blood serum and exosomal fraction from 5 to 7-month-old.

It has been reported that synaptic glutamate level shows a tendency to increase in AD [20,61], which can lead to excitotoxicity and neuronal death [21]. Other authors revealed a decreased level of glutamine in serum from AD patients, suggesting that glutamate metabolism could be altered [54]. An age-related reduction in glutamate levels in the whole-brain of SAMP8 mice from 5 to 7 mo mice was reported [30], which is in agreement with the decrease in glutamate content in the cerebral cortex and hippocampus from SAMP8 mice monitored from 2 to 14 mo animals [62]. Interestingly, a similar and significant reduction of glutamate levels is now reported in serum from 5 to 7 mo mice. In healthy humans, serum glutamate level was not significantly different between 38–47 and 56–69 years old [63], which is equivalent to 5 and 7 mo SAMP8 mice. Interestingly, serum levels of glutamate progressively decreased from healthy subjects over mild cognitive impairment to AD [64]. Therefore, the decrease in serum glutamate reported here could represent the progression of the disease from 5 to 7 mo mice in this model of AD. Brain-to-blood efflux of glutamate occurs through the blood-brain-barrier [65]. Thus, serum glutamate levels is the result of glutamate originated in blood cells and peripheral organs, and its efflux from the brain [66].
Additionally, RSV supplementation caused an age-dependent modulation in serum glutamate levels, which is in line with the neuroprotective effect exhibited by this polyphenol. In C57BL/6J mice, oral administration of RSV results in a maximal plasma concentration ($C_{\text{max}}$) of ~12 µM for 100 mg/kg b.w. [67], and ~32 µM for 240 mg/kg b.w. [68]. In 5-month-old SAMP8 mice, we have detected a serum RSV concentration of 0.044 µM after oral administration of 120 mg/kg b.w. for 8 weeks. This RSV level is not a $C_{\text{max}}$ value but the concentration found in serum when mice were sacrificed [69]. Taking into account that RSV acts as a non-selective ARs agonist [70], and these receptors can fine-tune the physiological activity of mGluRs [71], it is conceivable that the in vivo modulation of ARs in the brain from SAMP8 mice [29] might be responsible, at least in part, for the modulation of the glutamatergic system [30].

One interesting finding is the similarity of changes on the levels of ARs and mGluRs and their endogenous ligands (i.e., adenosine and glutamate) when comparing brain and serum derived results. Table 1 summarizes data obtained in the present work (i.e., blood serum) with that previously reported by our group concerning the adenosinergic [29] and the glutamatergic [30] signaling in the whole-brain of SAMP8 mice. Thus, adenosine, glutamate, and mGluR$_5$ are significantly and similarly decreased in serum and whole-brain during aging and in RSV treated mice of 5 months of age. A$_2$AR levels seem to be preserved in both serum and whole brain during aging or RSV supplementation. However, changes in adenosine A$_1$ receptors are more erratic, and it cannot be established a clear correlation between serum and whole brain values. This correspondence between serum and whole brain obtained values could be a promising discovery in the development of new and feasible biomarkers in AD.

### Table 1. Summary of changes detected in blood serum and whole-brain of SAMP8 mice.

| Parameter | AGING (from 5 to 7 Month-Old) | RSV Supplementation |
|-----------|-------------------------------|---------------------|
| A$_1$R    | Serum 5 Month-Old | 5 Month-Old | 7 Month-Old |
| $\downarrow$ 22%, $p > 0.05$ | $\downarrow$ 64%, ** | $\downarrow$ 26%, # | $\uparrow$ 46%, ## |
| A$_2$AR   | $\downarrow$ 58%, * | $\downarrow$ 44%, *** | $\downarrow$ 41%, # |
| mGluR$_5$ | $\downarrow$ 59%, ** | $\downarrow$ 52%, # | $\uparrow$ 38%, ## |
| Adenosine | $\downarrow$ 57%, *** | $\downarrow$ 39%, # | $\uparrow$ 38%, ## |
| Glutamate | $\downarrow$ 29%, *** | $\downarrow$ 27%, # | $\uparrow$ 31%, ## |

The percentage of increase ($\uparrow$) or decrease ($\downarrow$) detected on each parameter when comparing 7- versus 5-month-old control animals (AGING) or RSV treated versus corresponding control animals (RSV supplementation) on blood serum and whole-brain of SAMP8 mice. Similar changes are indicated in bold. $ns$, not significant. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ significantly different from 5-month-old control animals. $p < 0.05$, ## $p < 0.01$, ### $p < 0.001$ significantly different from corresponding control animals.

To date, many studies have aimed to decipher whether distinctive hallmarks of AD present in serum such as oxidative stress, mitochondrial dysfunction, high expression of pro-inflammatory cytokines [10], Aβ deposition [11] and p-Tau [72,73] have a predictive value in early diagnosis of AD [9]. Unfortunately, the weak correlation between CSF and plasma Tau together with the wide variability of Aβ levels reported in blood confer to these main hallmarks of AD a poor predictive and diagnosis value, suggesting the need for more accurate AD biomarkers. Fortunately, some other molecules present in peripheral blood such as neurotransmitter (e.g., glutamate, adenosine) [54] and related-receptors, cholesterol [74] or iron [75] that have been reported to be altered in AD could be used in combination with classical markers as potential blood-based biomarkers to aid in early diagnosis of AD in the future. In addition, the analysis of ARs and mGluRs in blood serum could be the basis of new biomarkers development in the context of AD.

Western blotting quantification of circulating receptors could be impractical for future clinical applications since this technique does not provide an absolute but relative quantification. Methodologies such as radioligand binding assay could be the ideal candidate to quantify circulating receptors in blood serum due to its high sensibility and absolute quantification. Nevertheless, we unsuccessfully tried to quantify A$_1$R, A$_2$AR, and mGluR$_5$ by using this method. Probably, the high abundance of albumin, which represents about 50% of the total protein content in blood serum samples, was interfering in
our assays. Transport of molecules is one of the main biological functions of albumin. In agreement, we observed a radioligand uptake by albumin alone, which interfered with the radioligand binding assay leading to not reliable results.

The biological significance of the presence of plasma membrane-receptors as extracellular vesicle cargo in blood serum has not been elucidated yet. This phenomenon could be involved in cell-to-cell communication and the regulation of GPCRs [76]. In fact, it has been reported in vitro that \( \text{A}_1 \text{R}, \text{A}_2\text{A} \text{R}, \) and \( \text{A}_2\text{B} \text{R} \) participate in modulating exosome production by cells expressing these receptors [77]. Despite the well-known molecular mechanisms by which GPCRs are desensitized and internalized in a cell, there is a lack of knowledge on how these receptors can be released into circulation or what types of stimuli may trigger their secretion. Our study opens new possibilities on how GPCRs might be modulated not only through desensitization and internalization but also by secreting receptors into circulation and later uptake by other cells, in a process where exosomes or extracellular vesicles seem to have a role. Future studies are required to delve into the biological significance of these findings.

5. Conclusions

Our data show: (i) evidence of the presence in serum and exosomes of some GPCRs such as \( \text{A}_1 \text{R}, \text{A}_2\text{A} \text{R}, \) and \( \text{mGluR}_5 \), (ii) its modulation by aging and resveratrol, and (iii) a potential association between brain and serum receptors levels. Even though further investigations are required to find out whether this association can also be found in humans, or to assess the origin of these receptors (e.g., are they brain-derived?), we suggest that the detection of these receptors in blood serum and exosomes would merit attention in the research of early diagnosis of AD.

Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/7/1628/s1, Scheme S1: Resveratrol treatment schedule. Figure S1: Ponceau red staining of electrophoresed proteins.

Author Contributions: Study conception and design: M.M. and M.P. Animal maintenance and tissue extraction C.G.-F. Acquisition of data: A.S.-M. and J.L.A. Analysis and interpretation of data: A.S.-M., J.L.A. and M.M. Drafting of manuscript: A.S.-M., J.L.A. and M.M. Critical revision: M.M. and M.P. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Ministerio de Economía y Competitividad (grant SAF2016-33307) to Mercè Pallas; and by UCLM (grant 2019-GRIN-27209 cofinanced with the European Union FEDER) and Junta de Comunidades de Castilla-La Mancha (JCCM) (grant PEII-2014-030-P) to Mairena Martín. Alejandro Sánchez-Melgar was the recipient of a postdoctoral grant (PRE-8002/2014) from JCCM.

Conflicts of Interest: The authors declare no conflict of interest. The sponsors had no role in the design, execution, interpretation, or writing of the study.

References
1. Apostolova, L.G. Alzheimer Disease. Continuum (Minneap Minn) 2016, 22, 419–434. [CrossRef]
2. Bao, W.; Jia, H.; Finnema, S.; Cai, Z.; Carson, R.E.; Huang, Y.H. PET Imaging for Early Detection of Alzheimer’s Disease: From Pathologic to Physiologic Biomarkers. PET Clin. 2017, 12, 329–350. [CrossRef] [PubMed]
3. Lautner, R.; Insel, P.S.; Skillback, T.; Olsson, B.; Landen, M.; Frisoni, G.B.; Herukka, S.K.; Hampel, H.; Wallin, A.; Minthon, L.; et al. Preclinical effects of APOE epsilon4 on cerebrospinal fluid Abeta42 concentrations. Alzheimers Res. Ther. 2017, 9, 87. [CrossRef]
4. Babapour Mofrad, R.; Schoonenboom, N.S.M.; Tijms, B.M.; Scheltens, P.; Visser, P.J.; van der Flier, W.M.; Teunissen, C.E. Decision tree supports the interpretation of CSF biomarkers in Alzheimer’s disease. Alzheimers Dement. (Anst.) 2019, 11, 1–9. [CrossRef] [PubMed]
5. Harari, O.; Cruchaga, C.; Kauwe, J.S.; Ainscough, B.J.; Bales, K.; Pickering, E.H.; Bertelsen, S.; Fagan, A.M.; Holtzman, D.M.; Morris, J.C.; et al. Phosphorylated tau-Abeta42 ratio as a continuous trait for biomarker discovery for early-Stage Alzheimer’s disease in multiplex immunoassay panels of cerebrospinal fluid. Biol. Psychiatry 2014, 75, 723–731. [CrossRef] [PubMed]
6. Bjerke, M.; Engelborghs, S. Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis. J. Alzheimers Dis. 2018, 62, 1199–1209. [CrossRef]
7. Mattsson, N.; Groot, C.; Jansen, W.J.; Landau, S.M.; Villemagne, V.L.; Engelborghs, S.; Mintun, M.M.; Lleo, A.; Molinuevo, J.L.; Jagust, W.J.; et al. Prevalence of the apolipoprotein E epsilon4 allele in amyloid beta positive subjects across the spectrum of Alzheimer’s disease. *Alzheimers Dement.* 2018, 14, 913–924. [CrossRef]

8. Martorana, A. Alzheimer’s Disease and the Routine Clinical Use of CSF Biomarkers. *CNS Neurol. Disord Drug Targets* 2017, 16, 407–413. [CrossRef]

9. Molinuevo, J.L.; Ayton, S.; Batsle, R.; Bednar, M.M.; Bittner, T.; Cummings, J.; Fagan, A.M.; Hampel, H.; Mielke, M.M.; Mikulskis, A.; et al. Current state of Alzheimer’s fluid biomarkers. *Acta Neuropathol.* 2018, 136, 821–853. [CrossRef]

10. Snyder, H.M.; Carrillo, M.C.; Grodstein, F.; Henriksen, K.; Jeromin, A.; Lovestone, S.; Mielke, M.M.; O’Bryant, S.; Sarasa, M.; Szegroe, M.; et al. Developing novel blood-Based biomarkers for Alzheimer’s disease. *Alzheimers Dement.* 2014, 10, 109–114. [CrossRef]

11. Koyama, A.; Okereke, O.I.; Yang, T.; Blacker, D.; Selkoe, D.J.; Grodstein, F. Plasma amyloid-beta as a predictor of dementia and cognitive decline: A systematic review and meta-analysis. *Arch. Neurol.* 2012, 69, 824–831. [CrossRef][PubMed]

12. Watt, A.D.; Perez, K.A.; Rembach, A.R.; Masters, C.L.; Barnham, K.J. Variability in blood-based amyloid-beta assays: The need for consensus on pre-analytical processing. *J. Alzheimers Dis.* 2012, 30, 323–336. [CrossRef]

13. Yang, J.; Liao, X.; Yu, J.; Zhou, P. Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target. *Curr. Med. Chem.* 2018, 25, 2260–2271. [CrossRef][PubMed]

14. Fredholm, B.B.; AP, I.J.; Jacobson, K.A.; Linden, J.; Muller, C.E. International Union of Basic and Clinical Pharmacology. LXXI. Nomenclature and classification of adenosine receptors—An update. *Pharmacol. Rev.* 2011, 63, 1–34. [CrossRef][PubMed]

15. Borea, P.A.; Gessi, S.; Merighi, S.; Vincenzi, F.; Varani, K. Pharmacology of Adenosine Receptors: The State of the Art. *Physiol. Rev.* 2018, 98, 1591–1625. [CrossRef]

16. Fredholm, B.B. Adenosine—A physiological or pathophysiological agent? *J. Mol. Med. (Berl.)* 2014, 92, 201–206. [CrossRef]

17. Cunha, R.A. How does adenosine control neuronal dysfunction and neurodegeneration? *J. Neurochem.* 2016, 139, 1019–1055. [CrossRef]

18. Albasanz, J.L.; Perez, S.; Barrachina, M.; Ferrer, I.; Martin, M. Up-Regulation of adenosine receptors in the frontal cortex in Alzheimer’s disease. *Brain Pathol.* 2008, 18, 211–219. [CrossRef]

19. Alonso-Andres, P.; Albasanz, J.L.; Ferrer, I.; Martin, M. Purine-Related metabolites and their converting enzymes are altered in frontal, parietal and temporal cortex at early stages of Alzheimer’s disease pathology. *Brain Pathol.* 2018, 28, 933–946. [CrossRef]

20. Kew, J.N.; Kemp, J.A. Ionotropic and metabotropic glutamate receptor structure and pharmacology. *Psychopharmacol. (Berl.)* 2005, 179, 4–29. [CrossRef]

21. Tzschentke, T.M. Glutamatergic mechanisms in different disease states: Overview and therapeutic implications—An introduction. *Amino Acids* 2002, 23, 147–152. [CrossRef][PubMed]

22. Renner, M.; Lacor, P.N.; Velasco, P.T.; Xu, J.; Contractor, A.; Klein, W.L.; Triller, A. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGlur5. *Neuron* 2010, 66, 739–754. [CrossRef][PubMed]

23. Albasanz, J.L.; Dalfo, E.; Ferrer, I.; Martin, M. Impaired metabotropic glutamate receptor/phospholipase C signaling pathway in the cerebral cortex in Alzheimer’s disease and dementia with Lewy bodies correlates with stage of Alzheimer’s-Disease-Related changes. *Neurobiol. Dis.* 2005, 20, 685–693. [CrossRef][PubMed]

24. Mao, Z.J.; Lin, H.; Hou, J.W.; Zhou, Q.; Wang, Q.; Chen, Y.H. A Meta-Analysis of Resveratrol Protects against Myocardial Ischemia/Reperfusion Injury: Evidence from Small Animal Studies and Insight into Molecular Mechanisms. *Oxid Med. Cell Longev.* 2019, 2019, 5793867. [CrossRef][PubMed]

25. Lange, K.W.; Li, S. Resveratrol, pterostilbene, and dementia. *Biofactors* 2018, 44, 83–90. [CrossRef]

26. Jiang, Z.; Chen, K.; Cheng, L.; Yan, B.; Qian, W.; Cao, J.; Li, J.; Wu, E.; Ma, Q.; Yang, W. Resveratrol and cancer treatment: Updates. *Ann. N. Y. Acad. Sci.* 2017, 1403, 59–69. [CrossRef]

27. Carter, L.G.; D’Orazio, J.A.; Pearson, K.J. Resveratrol and cancer: Focus on in vivo evidence. *Endocr. Relat. Cancer* 2014, 21, R209–R225. [CrossRef]

28. Malaguarnera, L. Influence of Resveratrol on the Immune Response. *Nutrients* 2019, 11, 946. [CrossRef]
29. Sanchez-Melgar, A.; Albasanz, J.L.; Palomera-Avalos, V.; Pallas, M.; Martin, M. Resveratrol Modulates and Reverses the Age-Related Effect on Adenosine-Mediated Signalling in SAMP8 Mice. *Mol. Neurobiol.* 2018. [CrossRef]

30. Sanchez-Melgar, A.; Albasanz, J.L.; Pallas, M.; Martin, M. Resveratrol Differently Modulates Group I Metabotropic Glutamate Receptors Depending on Age in SAMP8 Mice. *ACS Chem. Neurosci.* 2020. [CrossRef]

31. Giuliani, A.L.; Berchan, M.; Sanz, J.M.; Passaro, A.; Pizzicotti, S.; Vultaggio-Poma, V.; Sarti, A.C.; Di Virgilio, F. The P2X7 Receptor Is Shed Into Circulation: Correlation With C-Reactive Protein Levels. *Front. Immunol.* 2019, 10, 793. [CrossRef] [PubMed]

32. Hagiyara, S.I.; Hadsedir, B.; Heyman, M.B.; Chang, L.; Bhargava, A. Plasma Corticotropin-Releasing Factor Receptors and B7-2(+) Extracellular Vesicles in Blood Correlate with Irritable Bowel Syndrome Disease Severity. *Cells* 2019, 8, 101. [CrossRef]

33. Leon-Navarro, D.A.; Albasanz, J.L.; Martin, M. Hyperthermia-Induced seizures alter adenosine A1 and A2A receptors and 5'-nucleotidase activity in rat cerebral cortex. *J. Neurochem.* 2015, 134, 395–404. [CrossRef] [PubMed]

34. Akiguchi, I.; Pallas, M.; Budka, H.; Akiyama, H.; Ueno, M.; Han, J.; Yagi, H.; Nishikawa, T.; Chiba, Y.; Sugiyama, H.; et al. SAMP8 mice as a neuropathological model of accelerated brain aging and dementia: Toshio Takeda’s legacy and future directions. *Neuropathology* 2017, 37, 293–305. [CrossRef] [PubMed]

35. Wei, X.; Zhang, Y.; Zhou, J. Alzheimer’s disease-related gene expression in the brain of senescence accelerated mouse. *Neurosci. Lett.* 1999, 268, 139–142. [CrossRef]

36. Porquet, D.; Casadesus, G.; Bayod, S.; Vicente, A.; Canudas, A.M.; Vilaplana, J.; Pelegri, C.; Sanfeliu, C.; Camins, A.; Pallas, M.; et al. Dietary resveratrol prevents Alzheimer’s markers and increases life span in SAMP8. *Age (Dordr)* 2013, 35, 1851–1865. [CrossRef] [PubMed]

37. Flurkey, K.; Currer, J.; Harrison, D. The Mouse in Aging Research. In *The Mouse in Biomedical Research, 2nd ed.; Fox, J.G., Ed.; American College Laboratory Animal Medicine (Elsevier): Burlington, MA, USA, 2007*; pp. 637–672.

38. Castillo, C.A.; Albasanz, J.L.; Leon, D.; Jordan, J.; Pallas, M.; Camins, A.; Martin, M. Age-Related expression of adenosine receptors in brain from the senescence-Accelerated mouse. *Exp. Gerontol.* 2009, 44, 453–461. [CrossRef]

39. Hu, W.; Song, X.; Yu, H.; Sun, J.; Zhao, Y. Released Exosomes Contribute to the Immune Modulation of Cord Blood-Derived Stem Cells. *Front. Immunol.* 2020, 11, 165. [CrossRef]

40. Zhao, X.; Luo, C.; Mei, Q.; Zhang, H.; Zhang, W.; Su, D.; Fu, W.; Luo, Y. Aptamer-Cholesterol-Mediated Proximity Ligation Assay for Accurate Identification of Exosomes. *Anal. Chem.* 2020, 92, 5411–5418. [CrossRef]

41. Chen, P.; Ruan, A.; Zhou, J.; Huang, L.; Zhang, X.; Ma, Y.; Wang, Q. Extraction and identification of synovial tissue-derived exosomes by different separation techniques. *J. Orthop. Surg. Res.* 2020, 15, 97. [CrossRef]

42. Zhang, R.; Yang, D.; Zhou, C.; Cheng, K.; Liu, Z.; Chen, L.; Fang, L.; Xie, P. beta-Actin as a loading control for plasma-based Western blot analysis of major depressive disorder patients. *Anal. Biochem.* 2012, 427, 116–120. [CrossRef] [PubMed]

43. Vigelsø, A.; Dybboe, R.; Hansen, C.N.; Dela, F.; Helge, J.W.; Guadalupe Grau, A. GAPDH and beta-actin protein decreases with aging, making Stain-Free technology a superior loading control in Western blotting of human skeletal muscle. *J. Appl. Physiol. (1985)* 2015, 118, 368–394. [CrossRef] [PubMed]

44. Yamazaki, Y.; Kanekiyo, T. Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer’s Disease. *Int. J. Mol. Sci.* 2017, 18, 1965. [CrossRef] [PubMed]

45. Ott, B.R.; Jones, R.N.; Daiello, L.A.; de la Monte, S.M.; Stopa, E.G.; Johanson, C.E.; Denby, C.; Grammas, P. Blood-Cerebrospinal Fluid Barrier Gradient in Mild Cognitive Impairment and Alzheimer’s Disease: Relationship to Inflammatory Cytokines and Chemokines. *Front. Aging Neurosci.* 2018, 10, 245. [CrossRef] [PubMed]

46. Svenningsen, P.; Hall, H.; Sedvall, G.; Fredholm, B.B. Distribution of adenosine receptors in the postmortem human brain: An extended autoradiographic study. *Synapse* 1997, 27, 322–335. [CrossRef]

47. Kovacs, Z.; Dobolyi, A.; Juhasz, G.; Kekesi, K.A. Nucleoside map of the human central nervous system. *Neurochem. Res.* 2018, 35, 452–464. [CrossRef]

48. Burnstock, G.; Fredholm, B.B.; Verkhratsky, A. Adenosine and ATP receptors in the brain. *Curr. Top. Med. Chem.* 2011, 11, 973–1011. [CrossRef]
49. Fukumitsu, N.; Ishii, K.; Kimura, Y.; Oda, K.; Hashimoto, M.; Suzuki, M.; Ishiwata, K. Adenosine A(1) receptors using 8-dicyclopropylmethyl-1-[(11)C]methyl-3-propylxanthine PET in Alzheimer’s disease. *Ann. Nucl. Med.* 2008, 22, 841–847. [CrossRef]

50. Mishina, M.; Ishiwata, K. Adenosine receptor PET imaging in human brain. *Int. Rev. Neurobiol.* 2014, 119, 51–69. [CrossRef]

51. Lopes, L.V.; Cunha, R.A.; Ribeiro, J.A. Increase in the number, G protein coupling, and efficiency of facilitatory adenosine A2A receptors in the limbic cortex, but not striatum, of aged rats. *J. Neurochem.* 1999, 73, 1733–1738. [CrossRef]

52. Kovacs, Z.; Juhasz, G.; Dobolyi, A.; Bobest, M.; Papp, V.; Takats, L.; Kekesi, K.A. Gender- and age-dependent changes in nucleoside levels in the cerebral cortex and white matter of the human brain. *Brain Res. Bull.* 2010, 81, 579–584. [CrossRef]

53. Kovacs, Z.; Juhasz, G.; Palkovits, M.; Dobolyi, A.; Kekesi, K.A. Area, age and gender dependence of the nucleoside system in the brain: A review of current literature. *Curr. Top. Med. Chem.* 2011, 11, 1012–1033. [CrossRef] [PubMed]

54. Gonzalez-Dominguez, R.; Garcia-Barrera, T.; Gomez-Ariza, J.L. Metabolite profiling for the identification of altered metabolic pathways in Alzheimer’s disease. *J. Pharm. Biomed. Anal.* 2015, 107, 75–81. [CrossRef] [PubMed]

55. Simard, T.; Jung, R.; Labinaz, A.; Faraz, M.A.; Perry-Nguyen, D.; Pitcher, I.; Motazedian, P.; Gaudet, C.; et al. Evaluation of Plasma Adenosine as a Marker of Cardiovascular Risk: Analytical and Biological Considerations. *Am. Heart Assoc.* 2019, 8, e012228. [CrossRef] [PubMed]

56. Hamilton, A.; Vasefi, M.; Vander Tuin, C.; McQuaid, R.J.; Anisman, H.; Ferguson, S.S. Chronic Pharmacological mGluR5 Inhibition Prevents Cognitive Impairment and Reduces Pathogenesis in an Alzheimer Disease Mouse Model. *Cell Rep.* 2016, 15, 1859–1865. [CrossRef]

57. Kitamura, Y.; Zhao, X.H.; Ohnuki, T.; Takei, M.; Nomura, Y. Age-Related changes in transmitter glutamate and NMDA receptor/channels in the brain of senescence-accelerated mouse. *Neurosci. Lett.* 1992, 137, 169–172. [CrossRef]

58. Lee, M.; Lee, H.J.; Park, I.S.; Park, J.A.; Kwon, Y.J.; Ryu, Y.H.; Kim, C.H.; Kang, J.H.; Hyun, I.Y.; Lee, K.C.; et al. Abeta pathology downregulates brain mGluR5 density in a mouse model of Alzheimer. *Neuropsychopharmacology* 2018, 133, 512–517. [CrossRef]

59. Platt, S.R. The role of glutamate in central nervous system health and disease—A review. *Vet. J.* 2007, 173, 278–286. [CrossRef]

60. Kouchiwa, T.; Wada, K.; Uchiyama, M.; Kasezawa, N.; Niisato, M.; Murakami, H.; Fukuyama, K.; Yokogoshi, H. Age-related changes in serum amino acids concentrations in healthy individuals. *Clin. Chem. Lab. Med.* 2012, 50, 861–870. [CrossRef] [PubMed]

61. Corso, G.; Cristofano, A.; Sapere, N.; la Marca, G.; Angiolillo, A.; Vitale, M.; Fratangelo, R.; Lombardi, T.; Porcile, C.; Intrieri, M.; et al. Serum Amino Acid Profiles in Normal Subjects and in Patients with or at Risk of Alzheimer Dementia. *Dement. Geriatr. Cogn. Dis. Extra* 2017, 7, 143–159. [CrossRef]

62. Helms, H.C.C.; Nielsen, C.U.; Waagepetersen, H.S.; Brodin, B. Glutamate Transporters in the Blood-Brain Barrier. *Adv. Neurobiol.* 2017, 16, 297–314. [CrossRef] [PubMed]

63. Palomino, A.; Gonzalez-Pinto, A.; Aldama, A.; Gonzalez-Gomez, C.; Mosquera, F.; Gonzalez-Garcia, G.; Matute, C. Decreased levels of plasma glutamate in patients with first-episode schizophrenia and bipolar disorder. *Schizophr. Res.* 2007, 95, 174–178. [CrossRef]
67. Johnson, J.J.; Nihal, M.; Siddiqui, I.A.; Scarlett, C.O.; Bailey, H.H.; Mukhtar, H.; Ahmad, N. Enhancing the bioavailability of resveratrol by combining it with piperine. *Mol. Nutr. Food Res.* 2011, 55, 1169–1176. [CrossRef]

68. Sale, S.; Verschoyle, R.D.; Boocock, D.; Jones, D.J.; Wilsher, N.; Ruparelia, K.C.; Potter, G.A.; Farmer, P.B.; Steward, W.P.; Gescher, A.J. Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4′-tetramethoxystilbene. *Br. J. Cancer* 2004, 90, 736–744. [CrossRef]

69. Chang, J.; Rimando, A.; Pallas, M.; Camins, A.; Porquet, D.; Reeves, J.; Shukitt-Hale, B.; Smith, M.A.; Joseph, J.A.; Casadesus, G. Low-Dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer’s disease. *Neurobiol. Aging* 2012, 33, 2062–2071. [CrossRef]

70. Sanchez-Melgar, A.; Albasanz, J.L.; Guixa-Gonzalez, R.; Saleh, N.; Selent, J.; Martin, M. The antioxidant resveratrol acts as a non-selective adenosine receptor agonist. *Free Radic Biol. Med.* 2019, 135, 261–273. [CrossRef]

71. Leon-Navarro, D.A.; Albasanz, J.L.; Martin, M. Functional Cross-Talk between Adenosine and Metabotropic Glutamate Receptors. *Curr. Neuropharmacol.* 2018. [CrossRef]

72. Zetterberg, H. Review: Tau in biofluids-Relation to pathology, imaging and clinical features. *Neuropathol. Appl. Neurobiol.* 2017, 43, 194–199. [CrossRef] [PubMed]

73. Zetterberg, H.; Wilson, D.; Andreasson, U.; Minthon, L.; Blennow, K.; Randall, J.; Hansson, O. Plasma tau levels in Alzheimer’s disease. *Alzheimers. Res. Ther.* 2013, 5, 9. [CrossRef] [PubMed]

74. Pappolla, M.A.; Bryant-Thomas, T.K.; Herbert, D.; Pacheco, J.; Fabra Garcia, M.; Manjon, M.; Girones, X.; Henry, T.L.; Matsubara, E.; Zambon, D.; et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. *Neurology* 2003, 61, 199–205. [CrossRef] [PubMed]

75. Kweon, O.J.; Youn, Y.C.; Lim, Y.K.; Lee, M.K.; Kim, H.R. Clinical utility of serum hepcidin and iron profile measurements in Alzheimer’s disease. *J. Neurol. Sci.* 2019, 403, 85–91. [CrossRef] [PubMed]

76. Medapati, M.R.; Singh, A.; Korupally, R.R.; Henderson, D.; Klonisch, T.; Manda, S.V.; Chelikani, P. Characterization of GPCRs in extracellular vesicle (EV). *Methods Cell Biol.* 2017, 142, 119–132. [CrossRef] [PubMed]

77. Ludwig, N.; Azambuja, J.H.; Rao, A.; Gillespie, D.G.; Jackson, E.K.; Whiteside, T.L. Adenosine receptors regulate exosome production. *Purinergic Signal* 2020. [CrossRef] [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).